Patients with psoriasis may experience an increased risk of melanoma and hematologic cancers, however the risk is not increased by biologic therapies, according to a recent study conducted by Reddy and colleagues and published in the Journal of the American Academy of Dermatology.
To examine the risk of melanoma in patients with psoriasis, the researchers used case-control and retrospective cohort designs. In order to assess the risk of melanoma compared to a patients treatment regimen, the researchers used the Fisher exact test.
According to the findings, patients with psoriasis had 1.53 times greater risk of developing a malignancy compared to patients without psoriasis (P <.01). The researchers found no significant differences in malignancy risk among patients who were treated with topicals, systemics, or biologic agents. Additionally, patients with psoriasis and malignancy did not have significantly worse survival than patients without psoriasis.
The researchers noted that it is possible that patients developed malignancy after the follow-up time of the study.
—Julie Gould
Reference
Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Acad Dermatol. Published online April 2017. DOI: dx.doi.org/10.1016/j.jaad.2016.09.047.
Patients with psoriasis may experience an increased risk of melanoma and hematologic cancers, however the risk is not increased by biologic therapies, according to a recent study conducted by Reddy and colleagues and published in the Journal of the American Academy of Dermatology.
To examine the risk of melanoma in patients with psoriasis, the researchers used case-control and retrospective cohort designs. In order to assess the risk of melanoma compared to a patients treatment regimen, the researchers used the Fisher exact test.
According to the findings, patients with psoriasis had 1.53 times greater risk of developing a malignancy compared to patients without psoriasis (P <.01). The researchers found no significant differences in malignancy risk among patients who were treated with topicals, systemics, or biologic agents. Additionally, patients with psoriasis and malignancy did not have significantly worse survival than patients without psoriasis.
The researchers noted that it is possible that patients developed malignancy after the follow-up time of the study.
—Julie Gould
Reference
Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Acad Dermatol. Published online April 2017. DOI: dx.doi.org/10.1016/j.jaad.2016.09.047.
Patients with psoriasis may experience an increased risk of melanoma and hematologic cancers, however the risk is not increased by biologic therapies, according to a recent study conducted by Reddy and colleagues and published in the Journal of the American Academy of Dermatology.
To examine the risk of melanoma in patients with psoriasis, the researchers used case-control and retrospective cohort designs. In order to assess the risk of melanoma compared to a patients treatment regimen, the researchers used the Fisher exact test.
According to the findings, patients with psoriasis had 1.53 times greater risk of developing a malignancy compared to patients without psoriasis (P <.01). The researchers found no significant differences in malignancy risk among patients who were treated with topicals, systemics, or biologic agents. Additionally, patients with psoriasis and malignancy did not have significantly worse survival than patients without psoriasis.
The researchers noted that it is possible that patients developed malignancy after the follow-up time of the study.
—Julie Gould
Reference
Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Acad Dermatol. Published online April 2017. DOI: dx.doi.org/10.1016/j.jaad.2016.09.047.
